Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–S45 (2014).
Cholesterol Treatment Trialists' (CTT) Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
de Zeeuw, D. et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 3, 181–190 (2015).
Jacobson, T. A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 97, 44C–51C (2006).
Sidaway, J. E. et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 15, 2258–2265 (2004).
Moorhead, J. F., Chan, M. K., El-Nahas, M. & Varghese, Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2, 1309–1311 (1982).
Haynes, R. et al. Effects of lowering LDL cholesterol on progression of kidney disease. J. Am. Soc. Nephrol. 25, 1825–1833 (2014).
Wanner, C., Tonelli, M. & Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 85, 1303–1309 (2014).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
Colantonio, L. D. et al. Contrasting cholesterol management guidelines for adults with CKD. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014040400.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.W. has received lecture honoraria and travel assistance from Amgen, Sanofi, and Merck Sharp & Dohme. R.H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Haynes, R., Wanner, C. Statins in chronic kidney disease: time to move on?. Nat Rev Nephrol 11, 262–263 (2015). https://doi.org/10.1038/nrneph.2015.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.36